What are the recommended next‑step therapies for a patient with IgG‑lambda lymphoplasmacytic lymphoma (LPL) harboring the MYD88 L265P mutation and residual disease after six cycles of bendamustine and rituximab, with bone‑marrow biopsy showing about 10 % monotypic plasma cells?

Management of Residual LPL After Bendamustine-Rituximab

For this patient with MYD88 L265P-mutated lymphoplasmacytic lymphoma showing residual disease (10% monotypic plasma cells) after BR therapy, the critical first step is determining whether treatment is actually indicated, as the presence of residual disease alone does not mandate immediate therapy. 1

Assess Need for Treatment

Before considering salvage therapy, evaluate whether the patient meets criteria for treatment initiation:

• Symptomatic disease indicators:
  • Constitutional symptoms (fever, night sweats, weight loss) attributable to LPL
  • Symptomatic or bulky adenopathy/organomegaly
  • Cytopenias (hemoglobin <10 g/dL, platelets <100,000)
  • Hyperviscosity symptoms
  • Significant neuropathy or other IgG-related complications 1

If the patient is asymptomatic with stable blood counts and no disease-related complications, observation is appropriate. The pathology report indicates residual plasma cells are expected after treatment, as plasma cells in LPL are inherently more resistant to therapy than lymphocytes. 1 Best response may not occur until 12 months or longer after completing therapy.

If Treatment Is Required

Duration of Prior Response Determines Strategy

For patients who achieved durable remission (time to next therapy ≥3 years) with good tolerability to BR, repeating the same regimen is reasonable. 1

For shorter remissions or progressive disease, switch to an alternative class of agents:

Primary Salvage Options (in order of preference):

1. Ibrutinib monotherapy - This is the preferred option given:

   • Confirmed MYD88 L265P mutation (the key determinant of ibrutinib efficacy)
   • Grade B recommendation for first or second relapse in MYD88-mutated patients
   • Metabolic response rate of 92% in MYD88-mutated/CXCR4-wild-type patients 1
   • Documented efficacy in IgG-type LPL with MYD88 mutation 2, 3

2. Bortezomib-rituximab combination - Suitable alternative if:

   • Patient has no or minimal peripheral neuropathy (grade ≤2)
   • Achieves >80% overall response rate in salvage setting
   • Effective in IgG-secreting LPL 1, 4, 5

3. Alternative rituximab-based combinations:

   • Dexamethasone-rituximab-cyclophosphamide (DRC)
   • 70% of relapsed patients in DRC study were retreated with rituximab-based regimens with 82% response rates 1

Special Considerations for IgG-Type LPL

This patient has the uncommon IgG variant (rather than typical IgM). Key points:

• MYD88 L265P mutation confirms LPL diagnosis despite atypical immunoglobulin type 5, 2, 3, 6, 7
• Treatment approach follows standard LPL guidelines, not plasma cell neoplasm protocols
• Monitor for light chain-related complications (though less common than in IgM disease) 6
• IgG-type historically associated with poorer prognosis, making aggressive salvage more justified 6, 7

Stem Cell Transplant Consideration

If patient is ≤70 years old and has not had stem cells harvested:

• Consider stem cell collection during first remission for future autologous stem cell transplantation (ASCT)
• ASCT should be considered at first or second relapse if disease is chemosensitive, especially if first remission was short (<2 years)
• Do NOT offer ASCT for refractory disease 1

Common Pitfalls to Avoid

• Do not initiate rituximab maintenance - Not recommended outside clinical trials due to increased toxicity without clear benefit 1
• Do not use ibrutinib if MYD88 is wild-type - 0% response rate in MYD88 wild-type patients 1
• Avoid stem cell-toxic agents (fludarabine, high-dose alkylators) if patient is transplant-eligible and cells not yet harvested 4
• Do not treat residual disease reflexively - Monotypic plasma cells persist after therapy and do not alone indicate treatment failure

Monitoring Strategy If Observation Chosen

• Serial complete blood counts every 3 months
• IgG paraprotein quantification every 3-6 months
• Clinical assessment for symptoms, adenopathy, organomegaly
• Biochemical progression alone does not mandate treatment; wait for symptomatic or clinically significant progression (typically ≥12 months to assess full response) 1

The decision between observation versus immediate salvage therapy hinges entirely on whether the patient has symptomatic disease or significant cytopenias, not merely on the presence of residual monotypic plasma cells on bone marrow biopsy.